Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 12/20 | 0.41 |
| ▸ | CDK2 | P24941 | 12/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 12/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | YTHDF3 | Q7Z739 | 1/20 | 0.34 |
| ▸ | YTHDF1 | Q9BYJ9 | 1/20 | 0.34 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12505818 | 0.80 | HCAR2 (0.46) | HCAR2HCAR3CCNA2CDK2CCNA1 | |
| SCHEMBL15831691 | 0.73 | HCAR2 (0.45) | HCAR2HCAR3CCNA2CDK2CCNA1 | |
| SCHEMBL18176972 | 0.73 | HCAR2 (0.49) | HCAR2HCAR3CCNA2CDK2CCNA1 | |
| SCHEMBL23103095 | 0.73 | DAO (0.44) | HCAR2HCAR3CCNA2CDK2CCNA1 | |
| SCHEMBL17565544 | 0.72 | HCAR2 (0.44) | HCAR2HCAR3CCNA2CDK2CCNA1 | |
| SCHEMBL1668054 | 0.70 | HCAR2 (0.52) | HCAR2HCAR3CCNA2CDK2CCNA1 | |
| SCHEMBL1667926 | 0.69 | HCAR2 (0.47) | HCAR2HCAR3CCNA2CDK2CCNA1 | |
| SCHEMBL23133710 | 0.69 | DAO (0.40) | HCAR2HCAR3CCNA2CDK2CCNA1 | |
| SCHEMBL22815463 | 0.68 | HCAR2 (0.41) | HCAR2HCAR3CCNA2CDK2CCNA1 | |
| SCHEMBL2396815 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-3870577-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-114984003-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-115054600-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-3870576-B1 | BEZOPYRAZOLE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| EP-3870576-B1 | BEZOPYRAZOLE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| EP-3873607-B1 | QUINAZOLINYL-INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-11-29 | — | — | EP | disclosed |
| EP-3873607-B1 | QUINAZOLINYL-INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-11-29 | — | — | EP | disclosed |
| EP-4041729-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| EP-4041729-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2729448-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20130310377-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | Rhizen Phamaceuticals SA (CH) | 2013-11-21 | — | — | US | disclosed |
| US-8377970-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-19 | — | — | US | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| CN-102834382-A | Pyrazole derivatives as modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS S A | 2012-12-19 | — | — | CN | disclosed |
| EP-2509955-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL | Rhizen Pharmaceuticals S.A. (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20110105447-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-05 | — | — | US | disclosed |
| WO-2011042797-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL | ICOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-04-14 | — | — | WO | disclosed |
| WO-2008113795-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105447-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | HCAR2 268/4885HCAR3 252/4885CCNA2 3636/4885 |
| US-20130310377-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | HCAR2 268/4885HCAR3 252/4885CCNA2 3636/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | HCAR2 202/4885HCAR3 144/4885CCNA2 1114/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | HCAR2 3961/4885HCAR3 3562/4885CCNA2 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.